Galmed delays shareholder meeting for lack of quorum

Galmed Pharmaceuticals Ltd. postponed its Special General Meeting of Shareholders because too few shareholders were present to meet the required quorum.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. postponed its Special General Meeting of Shareholders because too few shareholders were present to meet the required quorum. The meeting, originally convened on March 4, 2026, will reconvene on March 5, 2026 at 4:00 p.m. Israel time at the offices of Meitar Law Offices in Ramat Gan. The report also states that this information is incorporated by reference into Galmed’s existing Form S-8 and Form F-3 registration statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Galmed Pharmaceuticals (GLMD) postpone its Special General Meeting?

Galmed Pharmaceuticals postponed its Special General Meeting because there was a lack of quorum. Too few shareholders were present or represented to formally conduct business, so the company adjourned the meeting and scheduled a new time to reconvene.

When and where will Galmed Pharmaceuticals (GLMD) reconvene the Special General Meeting?

Galmed will reconvene the Special General Meeting on March 5, 2026 at 4:00 p.m. Israel time. The meeting will be held at Meitar Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel, the company’s legal counsel.

What type of SEC filing did Galmed Pharmaceuticals (GLMD) use for this update?

Galmed used a Form 6-K, which is a current report filed by foreign private issuers. The filing informs investors about the adjournment and reconvening of its Special General Meeting and formally updates the market on this corporate event.

How does this Galmed Pharmaceuticals (GLMD) meeting update affect its registration statements?

The information in this report is incorporated by reference into Galmed’s Form S-8 and Form F-3 registration statements. This means the details about the adjourned and reconvened meeting are legally considered part of those existing registration documents.

Who signed the Galmed Pharmaceuticals (GLMD) Form 6-K about the adjourned meeting?

The Form 6-K was signed on behalf of Galmed Pharmaceuticals Ltd. by Allen Baharaff. He is identified in the filing as the company’s President and Chief Executive Officer, confirming the accuracy and authorization of the reported information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of March 2026

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On March 4, 2026, Galmed Pharmaceuticals Ltd. (the “Company”) convened a Special General Meeting of Shareholders (the “Meeting”), however, the Meeting was adjourned for one day to the same time and place due to lack of quorum. Accordingly, the Meeting will be reconvened on Thursday, March 5, 2026 at 4:00 p.m., Israel time at the at the offices of Meitar | Law Offices, legal counsel to the Company at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163 and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: March 4, 2026	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer